Summary
We have studied the disposition of perhexiline and its two major metabolites, M1 and M3, in healthy volunteers and in patients with biliary T-tube drains after cholecystectomy.
In healthy volunteers the genetic control for impaired hepatic oxidation is identical for debrisoquine, sparteine, and perhexiline. Poor metabolizers demonstrate markedly reduced production and excretion of the major metabolite, M1. Their production of M3 is also reduced, but to a lesser degree than for M1, confirming substrate stereoselectivity by hepatic oxidases.
Biphasic urinary elimination of M1 and M3 is seen in intact extensive oxidizers, whereas only the first phase is apparent in patients with biliary T-tube drainage. This suggests the possibility of enterohepatic recycling of these compounds, which may account for their prolonged elimination
More than 90% of an ingested dose of perhexiline maleate remains unaccounted for at 24h after ingestion, even in extensive metabolizers. A careful, radiolabelled tissue-distribution study is warranted to elucidate the complicated metabolic fate of perhexiline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Afzal M, Kafetzakis EM (1978) Assessment of perhexiline maleate in angiographically proven intractable angina: A double-blind trial. Am Heart J 96: 350–354
Nick J, Dudognon P, Escourolle R, Bakouche P, Nicholle MH, Reignier A, Hauw JJ, Ermidou S, Pollet S, Baumann M, Singlas E, Levy J (1978) Neurological disorders and perhexiline maleate therapy. Clinical study of 10 cases. Neuropathological, pharmacokinetic and biochemical studies. Rev Neurol 134: 103–114
Pessayre D, Birchara M, Feldmann G, Degott C, Potet F, Benhamou J (1979) Perhexiline maleate-induced cirrhosis. Gastroenterology 76: 170–177
Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD (1982) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284: 295–299
Cooper RG, Evans DAP, Whibley EJ (1984) Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21: 27–33
Oates NS, Shah RR, Idle JR, Smith RL (1984) The metabolic disposition of the stereoismers of perhexiline maleate and the influence of oxidation phenotype. Br J Clin Pharmacol 18: 307 P
Cooper RG, Harper G, Price AH, Evans DAP, Lockhart D (1986) Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids, by gas chromatography-electron capture detection. J Chromatogr Biomed Applic 381: 305–314
Oats NS, Shah RR, Idle JR, Smith RL (1982) Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 32: 81–89
Evans DAP, Harmer D, Downham DY (1983) The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet 20: 322–329
Wright GJ, Zeiger AV, Leeson GA, Lang JF (1973) The absorption excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 49 [Suppl 3]: 8–15
Singlas E, Goujet MA, Simon P (1978) Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neurophaty. Eur J Clin Pharmacol 14: 195–201
Cooper JDH, Turnell BC (1980) A rapid method for the determination of perhexiline in serum using gas-liquid chromatography. Ann Clin Biochem 17: 155–158
Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ (1981) High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 70: 320–322
Amoah AGB, Gould BJ, Parke DV (1984) Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr Biomed Applic 305: 401–409
Leeson GA, Zeiger AV, Lang JR, Wright GJ (1969) Metabolic fate of perhexiline-14C maleate. Fed Proc 28: 798
Boxenbaum HG, Jodhka GS, Ferguson AC, Riegelman S, Macgregor TR (1974) The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man. J Pharmacokinet Biopharm 2: 211–237
Tse FLS, Ballard F, Skinn T (1982) Estimating the fraction resorbed in drugs undergoing enterohepatic circulation. J Pharmacokinet Biopharm 10: 455–461
Amoah AGB, Gould BJ, Parke DV, Lockhart JDF (1986) Further studies on the pharmacokinetics of perhexiline in the human. Xenobiotica 16: 63–68
Smith RL (1973) The excretory function of bile. Chapman and Hall, London, pp 76–93
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cooper, R.G., Evans, D.A.P. & Price, A.H. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32, 569–576 (1987). https://doi.org/10.1007/BF02455990
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02455990